The Optimize trial tests the Svelte Drug Eluting Coronary Stent by comparing it to any commercially approved Abbot Vascular Xience or Boston Scientific Promus Drug Eluting Coronary Stent (control DES). The study is designed for patients diagnosed with symptomatic ischemic heart disease in one or two of their coronary vessels. The Optimize trial is currently closed to enrollment but is actively following patients enrolled in follow up for five years post-procedure.
PI: Mehdi Razavi, MD
SPONSOR: Svelte Medical Systems, Inc.